Table 1

Demographic characteristicsa, b

Characteristics

Clinical pathway, n = 238

No intervention, n = 238

Between-group difference, OR (95% CI)

P-valueb


Age, years (mean ± SD)

74.5 ± 10.8

74.0 ± 11.7

-

0.61

Male gender

138/238 (58.0) (51.4 to 64.3)

98/238 (41.2) (34.9 to 47.7)

1.97 (1.35 to 2.89)

< 0.001

Previous stroke

50/215 (23.3) (17.8 to 29.5)

57/207 (27.5) (21.6 to 34.2)

0.80 (0.50 to 1.27)

0.32

Current smoking status

29/229 (12.7) (12.4 to 22.5)

25/219 (11.4) (3.9 to 11.0)

1.13 (0.61 to 2.07)

0.77

Hypertension

132/229 (57.6) (51.0 to 64.1)

103/219 (47.0) (40.3 to 53.9)

1.53 (1.04 to 2.27)

0.03

Heart failure

86/229 (37.5) (30.0 to 42.8)

78/219 (35.6) (30.6 to 43.8)

1.09 (0.73 to 1.63)

0.69

Coronary heart disease

21/229 (9.2) (5.8 to 13.7)

29/219 (13.2) (9.1 to 18.5)

0.66 (0.35 to 1.25)

0.18

Peripheral vasculopathy

73/229 (31.9) (25.9 to 38.3)

46/219 (21.0) (15.8 to 27.0)

1.76 (1.12 to 2.76)

< 0.01

Diabetes mellitus

52/229 (22.7) (17.4 to 28.7)

73/219 (31.5) (27.1 to 40.0)

0.59 (0.38 to 0.91)

0.01

Diabetes mellitus (organ pathology)

7/229 (3.1) (1.2 to 6.2)

9/219 (4.1) (1.9 to 7.8)

0.74 (0.24 to 2.20)

0.62

COPD

24/229 (10.5) (6.8 to 15.2)

51/219 (23.3) (17.9 to 29.5)

0.48 (0.28 to 0.83)

< 0.01

Cerebrovascular pathology

60/229 (26.2) (20.6 to 32.4)

82/219 (37.4) (31.0 to 44.2)

0.59 (0.39 to 0.90)

0.01

Pressure ulcer

4/229 (1.8) (0.5 to 4.4)

11/219 (5.0) (2.5 to 8.8)

0.35 (0.09 to 1.22)

0.06

Hemiplegy

16/229 (7.0) (4.0 to 11.1)

22/219 (10.1) (6.4 to 14.8)

0.67 (0.33 to 1.38)

0.31

Nephropathy

10/229 (4.4) (2.1 to 7.9)

13/219 (5.9) (3.2 to 9.9)

0.72 (0.29 to 1.81)

0.52

Dementia

24/229 (10.5) (6.8 to 15.2)

10/219 (6.0) (2.2 to 8.2)

2.45 (1.08 to 5.63)

0.02

Hepatopathy

7/229 (3.1) (1.2 to 6.2)

6/219 (2.7) (1.0 to 5.9)

1.12 (0.33 to 1.82)

1

Cancer

Solid metastasis

2/229 (0.9) (0.1 to 3.1)

3/219 (1.4) (0.3 to 4.0)

0.63 (0.07 to 4.70)

0.68

Leukemia

2/229 (0.9) (0.1 to 3.1)

3/219 (1.4) (0.3 to 4.0)

0.63 (0.07 to 4.70)

0.68

Lymphoma

1/229 (0.4) (0.0 to 2.4)

0/219 (0.0) (0.0 to 1.7)

1.08 (0.14 to 1.92)

1

Others

11/229 (4.8) (2.4 to 8.4)

19/219 (8.7) (3.8 to 14.7)

0.53 (0.23 to 1.21)

0.10


aBecause of missing data denominators used to calculate percentages may differ from group totals (clinical pathway versus no intervention).

bValues are n/total n (%) (95% CI) unless otherwise indicated.

cP-values represent comparison of each characteristic between two groups (clinical pathway versus no intervention), and all P-values are two-sided.

Panella et al. BMC Medicine 2012 10:71   doi:10.1186/1741-7015-10-71

Open Data